Intensity Therapeutics initiated with a Buy at ThinkEquity

ThinkEquity initiated coverage of Intensity Therapeutics (INTS) with a Buy rating and $3 price target The company has pivoted its clinical focus, creating a “high-risk, high-reward investment opportunity” centered around a near-term catalyst, the analyst tells investors in a research note. The sees a “compelling opportunity” into the Phase 2 INVINCIBLE-4 study evaluating Intensity’s lead asset, INT230-6, in neoadjuvant triple-negative breast cancer.